Daklinza is an oral antiviral agent indicated for the treatment of chronic hepatitis c infection. It belongs to the class of direct-acting antivirals that target the ns5a protein of the hepatitis c virus. The drug binds to the ns5a region and disrupts viral assembly leading to inhibition of replication. By blocking viral replication the medication reduces the amount of circulating virus in the bloodstream. It is absorbed in the gastrointestinal tract and undergoes hepatic metabolism without producing active intermediates. The primary pharmacological action is the suppression of viral rna synthesis and prevention of new virion formation. This results in improved liver enzyme levels and histologic outcomes in patients receiving therapy. The overall effect is a decrease in viral load that supports sustained virologic response.

Daklinza is an antiviral medication used to treat chronic hepatitis c infection. Its active ingredient daclatasvir belongs to the class of ns5a replication complex inhibitors. The drug blocks the viral protein ns5a which is essential for the hepatitis c virus to replicate. By preventing ns5a function Daklinza stops the spread of the virus in the liver. This suppression allows the immune system to clear infected cells more effectively. The combined use of Daklinza with sofosbuvir improves the chances of achieving sustained virologic response. Clinical studies have shown that the regimen leads to viral eradication in the majority of patients. The mechanism relies on selective inhibition of a viral enzyme that is absent in human cells improving safety.

The most common side effects include mild fatigue, headache, and nausea. These symptoms often resolve without intervention and are generally transient. Some individuals may experience temporary dizziness or lightheadedness. Skin reactions such as mild rash or itching can occur in a small proportion of cases. Gastrointestinal discomfort, including occasional abdominal cramps, has also been reported. Serious adverse events are rare and may be observed.

The most common side effects include mild headache fatigue and nausea. Some people may notice temporary redness at the treatment site. Skin irritation can appear as a subtle rash. Digestive upset such as loose stools can occur occasionally. Drowsiness is reported in a small number of cases. Changes in taste sensation are occasionally described. Most symptoms are short lived and resolve without intervention.